{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.45","upperLimit":"33.73","value":"16.1"},{"groupId":"OG001","lowerLimit":"26.5","upperLimit":"54.0","value":"39.6"},{"groupId":"OG002","lowerLimit":"40.3","upperLimit":"65.4","value":"53.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"description":"ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy.\n\nsCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.\n\nCR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow.\n\nVGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \\< 100 mg/24 hours.\n\nPR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \\< 200 mg per 24 hours.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants previously treated with bortezomib received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG000","title":"Part 1: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG001","title":"Part 2: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 of Cycle 1. If all doses were well-tolerated the dose was escalated to 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 for subsequent cycles, for up to 12 cycles.","id":"OG002","title":"Part 2: Carfilzomib 20/27 mg/m²"}],"paramType":"NUMBER","populationDescription":"The Response Evaluable Subset population consists of all treated patients with measurable disease at Baseline as assessed by M-protein or by quantitative serum Ig for certain patients with IgA myeloma, and with a baseline and at least 1 post-baseline disease assessment.\n\nPatients whose disease was only measurable by SFLC were excluded.","reportingStatus":"POSTED","timeFrame":"Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.","title":"Best Overall Response Rate (ORR) in the Response Evaluable Subset Population","type":"PRIMARY","unitOfMeasure":"percentage of participants"}